Clinical trials
Solid Cancers clinical trials
Below are recruiting solid cancers clinical trials, each written for real people, not researchers. We’re tracking 901 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06501040Recruiting
Learning about cancer clinical trials for interested adults
This study aims to help people learn more about cancer clinical trials and become more comfortable with the idea of joining one. It is open to adults connected to Karmanos Cancer Institute who want to learn and give their permission to participate.
Detroit, MichiganAges 21 years+ - NCT00992303Recruiting
Collecting tissue samples during radiation for people with cancer
This study collects tissue samples from people with cancer while they are getting radiation therapy. It also includes healthy participants, to help researchers compare samples and better understand cancer and treatment.
Dallas, TexasAges 18 years+ - NCT07577206RecruitingEarly Phase 1
New PET Scan Tracer for Advanced Solid Cancers
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Naples, ItaliaAges 18 years+ - NCT06657222RecruitingPhase 1/Phase 2
Study of TUB-030 for advanced solid tumors
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT07672483RecruitingPhase 1
Gene therapy for solid tumors that returned after treatment
This trial tests a new type of gene therapy that uses your own immune cells (called myeloid cells) engineered to produce a protein (IL-12) to fight your cancer. It is for people with solid tumors that have not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT04897321RecruitingPhase 1
CAR T therapy for children with B7-H3 solid tumors
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
Memphis, TennesseeAges Up to 21 years - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT05059678Recruiting
Parenting support for families facing advanced cancer
This study tests a program to help parents with advanced cancer support their children and manage family life during treatment. It may help you feel more confident as a parent while coping with cancer.
Houston, TexasAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Princeton, New JerseyAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT04551378Recruiting
Study of how COVID affected young people with cancer
This study looks at how the COVID-19 pandemic affected the experiences of teenagers and young adults with cancer, including people who finished treatment. It may help improve support for cancer patients and survivors during public health crises.
Houston, TexasAges 18–39 - NCT06895031RecruitingPhase 2
JYP0015 for advanced solid tumors with RAS mutations
This trial tests a new drug called JYP0015 for people with advanced solid tumors that have a specific change in the RAS gene. It aims to see if the drug can help when other treatments have stopped working or caused too many side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07291011Recruiting
Mindfulness for underserved cancer patients in Minnesota
This study tests an online mindfulness program (stress-reducing techniques) to help people with cancer who live in rural areas feel better emotionally. It is designed for those who are feeling significant distress.
Rochester, MinnesotaAges Any age - NCT07220447RecruitingEarly Phase 1
L-Theanine for relaxation and mood in cancer survivors
This trial tests whether a natural supplement called L-theanine, found in green tea, can help cancer survivors feel more relaxed and improve their mood. You may qualify if you have finished cancer treatment, have been in surveillance for at least 6 months, and feel anxious.
Duarte, CaliforniaAges 18 years+ - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06989489Recruiting
Daily oral chemo adherence support program
This study is testing a program to help people stick with their daily oral chemo pill. It is for adults who have been taking a single oral cancer treatment for at least six months and want extra support.
Chapel Hill, North CarolinaAges 21 years+ - NCT06304168Recruiting
Blood, tissue, and urine tests to detect cancer early
This study is testing whether simple blood, tissue, and urine samples can help find cancer earlier and identify where it started. Participating could help improve future cancer detection for everyone.
Rochester, MinnesotaAges 18 years+ - NCT06021626RecruitingPhase 1
Study of CRD3874-SI for advanced solid tumors
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Basking Ridge, New JerseyAges 18 years+ - NCT05955924RecruitingPhase 3
Nicotinamide to prevent skin cancer after organ transplant
This trial tests nicotinamide (a vitamin-like medicine) to help prevent new keratinocyte skin cancers in people who have had a kidney, liver, heart, or lung transplant. It may lower the chance of developing new skin tumors while you continue your usual transplant anti-rejection medicines.
Calgary, AlbertaAges 18 years+ - NCT06598371RecruitingPhase 1/Phase 2
Study of engineered immune cells for advanced solid tumors
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
Houston, TexasAges 18 years+ - NCT06008392Recruiting
Mayo Clinic cancer genetics research study
This study collects blood, saliva, tumor tissue, or hair samples to look for inherited and tumor-related gene changes that may explain your cancer, guide prevention, or help find better treatments. You can join if you are a Mayo Clinic patient with cancer and your doctor has ordered genetic testing.
Scottsdale, ArizonaAges 18 years+
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid cancers?
- Yes. Clin2 currently lists 901 recruiting solid cancers studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid cancers trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid cancers trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.